Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides

McDonagh, 1998, Biochemical detection of left ventricular systolic dysfunction, Lancet, 351, 9, 10.1016/S0140-6736(97)03034-1 Hobbs, 2002, Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations, BMJ, 324, 1498, 10.1136/bmj.324.7352.1498 Ng, 2003, Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography, Eur J Heart Failure, 5, 775, 10.1016/S1388-9842(03)00154-5 Hunt, 2001, ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary, J Am Coll Cardiol, 38, 2101, 10.1016/S0735-1097(01)01683-7 2001, Guidelines for the diagnosis and treatment of chronic heart failure, Eur Heart J, 22, 1527, 10.1053/euhj.2001.2783 Ng, 2003, Diagnosis of heart failure using urinary natriuretic peptides, Clin Sci, 106, 129, 10.1042/CS20030234 Mistry, 2001, Differential expression and synthesis of natriuretic peptides determines natriuretic peptide receptor expression in primary cultures of human proximal tubular cells, J Hypertens, 19, 255, 10.1097/00004872-200102000-00012 Heidenreich, 2004, Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction, J Am Coll Cardiol, 43, 1019, 10.1016/j.jacc.2003.10.043 Totsune, 1996, Urinary immunoreactive brain natriuretic peptide in patients with renal disease, Regul Pept, 63, 141, 10.1016/0167-0115(96)00035-3 Heringlake, 2004, Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers, J Appl Physiol, 97, 173, 10.1152/japplphysiol.01196.2003